Sifalimumab

Sifalimumab
Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg​.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetInterferon α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6518H10008N1724O2032S38
Molar mass146252.08 g·mol−1
 NY (what is this?)  (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.